When most people think about cancer, they think of bad luck, lifestyle choices, or something that “just happens.” Very few ...

The Urology Care Foundation and the Prostate Cancer Foundation have created a new educational guide on genetic tests to guide ...

Up to 5% of Americans may carry genetic variants associated with cancer risk, according to a cross-sectional analysis.The ...

Myriad Genetics, Inc. MYGN is well-poised to grow in the coming quarters due to its impressive cadence of product launches. The company is also progressing well in its refreshed long-term strategy to ...

FLGT currently has a market capitalization of $853.49 million.

New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer TestSALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN ...

Germline pathogenic variants contribute to 15%-20% of ovarian cancer cases, with BRCA1/2 mutations accounting for 65%-85% of these cases. Disparities in genetic testing uptake exist across racial, ...

The Prostate Cancer Foundation (PCF) is proud to announce the launch of an interactive website and downloadable guide, Somatic and Germline Genetic Testing for Patients with Advanced Prostate ...

Please provide your email address to receive an email when new articles are posted on . Nearly all individuals who self-navigated the entire online platform completed germline testing. The platform ...

We are at a transformative moment in oncology. Remarkable advancements have led to the identification of biomarkers that can predict treatment response, tests that can detect cancer risk before ...

Germline genetic testing for patients with gynecologic cancers can be conducted in parallel with tumor somatic testing via a targeted sequencing assay by primary oncologists, researchers reported.